Half-life extended factor VIII for the treatment of hemophilia A
Author:
Affiliation:
1. Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation; Hannover Medical School; Hannover Germany
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.12929/fullpdf
Reference18 articles.
1. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007
2. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study;Gouw;Blood,2007
3. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A;Bjorkman;Eur J Clin Pharmacol,2009
4. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients;Powell;Blood,2012
5. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A;Mahlangu;Blood,2014
Cited by 74 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Emicizumab as a Promising Form of Therapy for Type A Hemophilia - AReview of Current Knowledge from Clinical Trials;Current Protein & Peptide Science;2024-11
2. Liposomal factor VIII as an efficient pharmaceutical system for the treatment of hemophilia;IRAN J BASIC MED SCI;2024
3. Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada;Haemophilia;2024-02-20
4. In vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice;Molecular Therapy - Nucleic Acids;2023-12
5. Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey;Patient Preference and Adherence;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3